Roche’s obinutuzumab receives a positive CHMP recommendation for SLE, supported by Phase III ALLEGORY data showing a 76.7% SRI-4 response rate.
Written By: Aasritha Thippavajjala, PharmD
Reviewed By: Pharmacally Editorial Team
Roche has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Gazyva/Gazyvaro (obinutuzumab) in adults with active systemic lupus erythematosus (SLE) receiving standard therapy. The recommendation marks an important regulatory development for the anti-CD20 monoclonal antibody, following positive results from the Phase III ALLEGORY trial.
The recommendation is supported by clinical evidence demonstrating improvements in disease activity, glucocorticoid control and disease flare outcomes. Detailed ALLEGORY results were published in the New England Journal of Medicine in March 2026.
ALLEGORY Phase III Trial: Study Design and Treatment
ALLEGORY (NCT04963296) was a multicentre, randomised, double-blind, placebo-controlled Phase III study evaluating obinutuzumab in adults with active, autoantibody-positive SLE receiving standard therapy.
The trial randomised 303 participants in a 1:1 ratio to receive intravenous obinutuzumab 1,000 mg (151 patients) or placebo (152 patients), alongside standard treatment. Study doses were administered on Day 1 and Weeks 2, 24 and 26.
The primary endpoint was the proportion of patients achieving a SLE Responder Index-4 (SRI-4) response at Week 52. The study excluded patients with proliferative or membranous lupus nephritis, an important consideration when interpreting the applicability of its findings across the broader SLE population.
Primary Endpoint: Significant Improvement in SRI-4 Response
Obinutuzumab met the primary endpoint, with 76.7% of patients achieving an SRI-4 response at Week 52, compared with 53.5% receiving placebo. The adjusted treatment difference was 23.1 percentage points (95% CI: 12.5–33.6; P<0.001).
SRI-4 requires at least a four-point reduction in the SLEDAI-2K disease activity score, without worsening in the British Isles Lupus Assessment Group (BILAG) index or Physician’s Global Assessment. The composite endpoint also accounts for specified treatment discontinuations, rescue medication and other intercurrent events.
The 23.1-percentage-point difference indicates a clinically meaningful improvement in overall disease response when obinutuzumab is added to standard therapy.
Five Key Secondary Endpoints Demonstrate Consistent Benefits
Obinutuzumab also demonstrated statistically significant improvements across all five key secondary endpoints.
BICLA response at Week 52 was achieved by 62.0% of patients receiving obinutuzumab, compared with 40.1% in the placebo group. Sustained glucocorticoid control, defined as maintaining a prednisone-equivalent dose of 7.5 mg/day or less from Week 40 through Week 52, was achieved by 80.0% and 54.1%, respectively.
A sustained SRI-4 response from Week 40 through Week 52 occurred in 72.0% of patients receiving obinutuzumab, compared with 46.4% receiving placebo. SRI-6 response rates at Week 52 were 68.9% and 38.9%, respectively.
Obinutuzumab also reduced the hazard of a first BILAG-defined disease flare through Week 52 (HR: 0.58; 95% CI: 0.40–0.82; P=0.002), representing a 42% lower hazard compared with placebo. Median time to first flare could not be estimated in the obinutuzumab group, compared with 52.3 weeks in the placebo group.
Together, these findings suggest that the treatment effect extends beyond a reduction in disease activity scores, encompassing sustained response, glucocorticoid control and flare prevention.
Remission and Low Disease Activity Outcomes
Additional supportive secondary outcomes further demonstrated improvements in disease control. DORIS remission at Week 52 was achieved by 33.8% of patients receiving obinutuzumab, compared with 13.8% receiving placebo. Lupus Low Disease Activity State (LLDAS) was achieved by 57.6% and 25.0%, respectively.
Although these outcomes were not among the five key secondary endpoints, they provide additional evidence of the treatment’s potential to help patients reach clinically relevant disease-control targets.
Safety and Mechanism of Action
Adverse events occurred in 88.7% of patients receiving obinutuzumab and 81.5% receiving placebo. Serious adverse events were reported in 15.9% and 11.9%, respectively. One death occurred in the obinutuzumab group and three in the placebo group during the double-blind treatment period. These mortality figures do not establish a treatment-related survival benefit.
Obinutuzumab is a glycoengineered Type II anti-CD20 monoclonal antibody that targets CD20-expressing B cells. Its mechanism promotes B-cell depletion through enhanced antibody-dependent cellular cytotoxicity and other immune-mediated mechanisms. B cells contribute to SLE pathogenesis through autoantibody production, antigen presentation and inflammatory signalling.
Clinical Interpretation and Regulatory Significance
The CHMP recommendation adds an important regulatory dimension to the ALLEGORY findings. The combination of improved disease response, sustained glucocorticoid control and reduced flare risk supports further development of B-cell-directed treatment in SLE.
The glucocorticoid findings are particularly relevant because sustained steroid exposure can contribute to cumulative treatment-related toxicity. However, the 52-week results do not independently establish long-term prevention of organ damage, durable remission or improved survival.
The recommendation represents a significant step towards expanding obinutuzumab’s use beyond lupus nephritis into systemic lupus erythematosus. Final European Commission marketing authorisation remains a separate regulatory decision.
References
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE) 13 November 2026
Furie RA et al. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine. 2026;395:243–254.
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants with Systemic Lupus Erythematosus (ALLEGORY) ClinicalTrials.gov. NCT04963296.
About the Writer
Aasritha Thippavajjala (Linkedin) is a pharm D student and aspiring medical writer with medical writing, clinical training experience and a strong interest in clinical research and patient safety She has hands-on exposure to clinical pharmacy activities including medication profile assessment, clinical case review, identification of potential drug-related problems, ADR awareness, patient counselling, and clinical documentation. She has also gained experience in medical literature review, evidence synthesis, and scientific communication through her published review article on digital twin-based patient simulation and her poster presentation at the 74th Indian Pharmaceutical Congress. Certified in ICH Good Clinical Practice (E6(R3)) and Scientific Writing in Health Research, she is passionate about applying her clinical knowledge and research skills to medical writing ,clinical research and contributing to accurate, evidence-based healthcare.